ACCESS Newswire

Representing Animals Foundation

6.6.2024 13:35:39 CEST | ACCESS Newswire | Press release

Share
Dogs Thrive on Vegan Diets, Demonstrates the Most Comprehensive Study So Far

WINCHESTER, UK / ACCESSWIRE / April 23, 2024 / The longest, most comprehensive peer-reviewed study so far has demonstrated that dogs fed nutritionally-sound vegan diets maintain health outcomes as well as dogs fed meat. The study, published in leading scientific journal PLOS ONE, comprehensively assessed the health of 15 dogs by analysing blood cells and biochemistry, blood nutrient levels, urine, veterinary clinical parameters, and monthly pet owner questionnaires. The dogs were fed solely vegan diets based on pea protein for an entire year - just under one tenth of an average dog lifespan, or around seven human years.

To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.
Dr. Linde with 'Rylee'

Overweight or obese dogs lost weight, whilst the remainder maintained normal weight. No clinically significant changes occurred within blood and urine. Blood levels of amino acids and vitamins were all generally maintained.

In a few cases, previous deficiencies following a meat-based diet either improved or disappeared, including L-taurine and L-carnitine (important for cardiac health), vitamin D (indispensable for immunity and bone health), and folate (required to produce red blood cells).

The study was particularly interesting, given recent suggestions that peas might contribute to heart disease in dogs in the US. Although no credible evidence has been found, such concerns have persisted in some quarters. In the current study, dogs were fed pea-based vegan pet food, for one year. Blood markers of cardiac health were assessed, with no signs of heart disease found. Indeed, in some cases indicators of cardiac health improved.

Stated lead researcher, veterinarian Dr. Annika Linde from the Western University of Health Sciences near Los Angeles says, "Evolutionary adaptations have resulted in a digestive system that enables dogs to maintain health on nutritionally complete omnivorous diets, including those free of animal ingredients. Our study offers new evidence on outcomes in clinically healthy dogs who thrive without consumption of animal-derived ingredients. Notably, foods produced independent of factory farming are also more sustainable and ethical."

Study co-author Dr. Melgarejo highlighted the potential environmental benefits of such diets, "If dogs and cats in the U.S. were their own nation, they would rank fifth in global meat consumption, surpassed only by Russia, Brazil, USA, and China, according to the UCLA Institute of the Environment and Sustainability."

Veterinary Professor Andrew Knight has published several of the key studies in this field, including very large-scale studies showing that both dogs and cats normally achieve equivalent or superior health outcomes, when fed nutritionally-sound vegan diets. He also analysed the environmental benefits of vegan pet diets in a major recent study. He stated that "If all the world's dogs went vegan, it would save more greenhouse gases than those emitted by the UK, land larger than Mexico, and 450 million additional people could be fed with food energy savings - more than the entire EU population. With 13 studies now demonstrating good health outcomes achieved by nutritionally-sound vegan pet diets, and several others demonstrating major environmental benefits, a compelling case now exists for environmentally-friendly vegan pet diets."

Contact Information:

Andrew Knight
Veterinary Professor of Animal Welfare
andrew.knight@winchester.ac.uk

SOURCE: Representing Animals Foundation

To view this piece of content from stats.nwe.io, please give your consent at the top of this page.

View the original press release on newswire.com.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Anew Climate Expands European Forest Carbon Portfolio Through Ten-Year Agreement with Sweden's EKEN1.10.2026 15:00:00 CEST | Press release

HOUSTON, TX / ACCESS Newswire / October 1, 2026 / Anew Climate (Anew), one of the world's largest developers and marketers of carbon credits, announced a ten-year agreement with EKEN Financing Value Added Forestry (EKEN) to bring Swedish improved forest management (IFM) credits to corporate buyers worldwide. The agreement extends Anew's European forest carbon portfolio, which it maintains alongside millions of acres of managed forestland across North America. Under the collaboration, Anew will serve as the exclusive commercialization partner for credits generated from projects developed by EKEN, handling purchaser engagements, structuring, and portfolio integration for corporate buyers in Europe and internationally. EKEN is preparing the project for development under VM0045, Verra's methodology for improved forest management using dynamic matched baselines from national forest inventories. While many conventional forest carbon baselines rest on a projection of what a landowner would hy

Karbon‑X (OTCQB:KARX) Reports Record Fiscal 2026 Revenue of $55.9 Million as Company Scales Global Carbon Market Operations1.10.2026 14:30:00 CEST | Press release

CALGARY, AB / ACCESS Newswire / October 1, 2026 / Karbon‑X Corp. (OTCQB:KARX) ("Karbon‑X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets, today reported financial and operational results for the fiscal year ended May 31, 2026, reflecting a significant increase in operating scale across its carbon credit trading and project development activities. Karbon‑X generated record fiscal 2026 revenue of $55.9 million, compared with $3.16 million in fiscal 2025, representing an increase of approximately 1,670% year over year. Gross profit was $0.86 million, compared with $0.80 million in the prior year. Fiscal 2026 results reflected a shift in revenue mix toward high-volume, lower-margin trading activity as Karbon‑X completed its first full year of large-scale carbon credit trading. "Fiscal 2026 moved Karbon-X into a new stage of commercial growth," said Chad Clovis, Chief Executive Officer of Karbon-X. "Revenue reached nearly eighteen

Surmodics Acquires Alta Biomed Business, Expanding Hemocompatible Surface Technology and Analytical Testing Capabilities1.10.2026 14:00:00 CEST | Press release

HORSHAM, PA / ACCESS Newswire / October 1, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced that it has acquired the business of Alta Biomed, a Carlsbad, California-based medical device coating and testing services company specializing in surface technologies for vascular and other medical devices. The acquisition is a strategic addition to Surmodics' growing portfolio of hemocompatible and biocompatible surface technologies. It brings Alta Biomed's proprietary PzF™ thin-film surface modification technology to Surmodics, adding an established anti-thrombotic, anti-inflammatory and pro-healing option that joins Surmodics' existing hemocompatible portfolio. "As medical device innovation advances in neuromodulation, brain-computer interfaces, neurovascular, structural heart, and venous and arterial technologies, engineers and scientists need a broader range of surface technology options to address i

PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release

PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path

Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans30.9.2026 15:50:00 CEST | Press release

NEW YORK, NY / ACCESS Newswire / September 30, 2026 / Innodata Inc. (Nasdaq:INOD) today announced the opening of a new R&D laboratory that is designed to generate the data needed to train the next generation of human-like robots and independently validate the performance data that robots generate internally. Innodata developed the lab in collaboration with Vicon, a leader in motion capture who consulted on the lab design and continues to provide technical consulting. The New Jersey-based lab is equipped with high-precision, low-latency infrared optical tracking cameras that measure movement down to the sub-millimeter level-a degree of accuracy that methods such as wearable inertial measurement unit (IMU) sensors and single-camera (monocular) video analysis typically cannot match. The lab addresses an urgent need for high-quality training data for humanoids, industrial robots, and other forms of physical AI. While many other data providers infer 3D motion by analyzing 2D video, Innodata

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye